GMPV-12 / Genematrix - LARVOL DELTA

Jinmatrix…announced on the 17th that its cervical cancer treatment vaccine candidate, ’GMPV-12’, has been registered for a US patent. [Google translation] (BioTimes) - "Jinmatrix is ​​preparing for clinical trials of GMPV-12 following the registration of its US patent, and also plans to pursue joint development and technology transfer cooperation with global pharmaceutical companies."

Patent • Cervical Cancer